GT200900333A - Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. - Google Patents

Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Info

Publication number
GT200900333A
GT200900333A GT200900333A GT200900333A GT200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A
Authority
GT
Guatemala
Prior art keywords
compounds
serotonine
modulation
receiver
kinoline
Prior art date
Application number
GT200900333A
Other languages
English (en)
Inventor
turner Sean
Braje Wilfried
Haupt Andreas
Lange Udo
Drescher Karla
Wicke Karsten
Unger Liliane
Mezler Mario
Wernet Wolfgang
Mayrer Mathias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900333A publication Critical patent/GT200900333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON NUEVOS COMPUESTOS DE QUINOLINA DE LA FÓRMULA I Y SALES DE LOS MISMOS. LOS COMPUESTOS TIENEN PROPIEDADES TERAPÉUTICAS VALIOSAS Y SON APROPIADOS, EN PARTICULAR, PARA TRATAR ENFERMEDADES QUE RESPONDEN A LA MODULACIÓN DEL RECEPTOR DE SEROTONINA 5-HT6. EN LA FÓRMULA I, R ES UNA PORCIÓN DE LA FÓRMULA EN DONDE * INDICA EL SITIO DE UNIÓN AL RADICAL QUINOLINILO Y EN DONDE A,B,X',Y,Q,R1,R2,R3,R4,R5,M,N,P,Q,RA, RB,X Y AR SON COMO SE DEFINEN EN LA REIVINDICACIÓN 1.
GT200900333A 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. GT200900333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113962 2007-08-07

Publications (1)

Publication Number Publication Date
GT200900333A true GT200900333A (es) 2015-10-14

Family

ID=39809897

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900333A GT200900333A (es) 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Country Status (23)

Country Link
US (2) US8293913B2 (es)
EP (1) EP2185555B1 (es)
JP (1) JP5501230B2 (es)
KR (1) KR20100039300A (es)
CN (1) CN101687866B (es)
AU (1) AU2008285652B2 (es)
BR (1) BRPI0812853A2 (es)
CA (1) CA2691529C (es)
CO (1) CO6251268A2 (es)
CR (1) CR11187A (es)
DO (1) DOP2009000291A (es)
EC (1) ECSP099831A (es)
ES (1) ES2574154T3 (es)
GT (1) GT200900333A (es)
HK (1) HK1143588A1 (es)
IL (1) IL202706A (es)
MX (1) MX2009013956A (es)
NZ (1) NZ581986A (es)
RU (1) RU2483068C2 (es)
TW (1) TWI478919B (es)
UA (1) UA99626C2 (es)
WO (1) WO2009019286A1 (es)
ZA (1) ZA200909075B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CN106233449B (zh) * 2014-04-30 2019-07-12 科迪华公司 用于衬底涂覆的气垫设备和技术
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
CN107922412B (zh) 2015-09-24 2021-02-23 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
WO2017050791A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
CA2984585A1 (en) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10160744B2 (en) 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
US20220227773A1 (en) * 2019-05-30 2022-07-21 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Fused ring compound, preparation method therefor and use thereof
US20230121337A1 (en) * 2021-06-26 2023-04-20 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237590C (en) * 1995-11-13 2011-07-19 Hoechst Aktiengesellschaft Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE10000739A1 (de) 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP4455064B2 (ja) * 2002-03-27 2010-04-21 グラクソ グループ リミテッド キノリン誘導体および５−ｈｔ６リガンドとしてのその使用
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
MXPA06005019A (es) * 2003-11-03 2006-07-06 Warner Lambert Co Nuevos inhibidores de la recaptacion de norpinefrina para el tratamiento de transtornos del sistema nervioso central.
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
ES2341489T3 (es) 2005-07-27 2010-06-21 F.Hoffmann-La Roche Ag Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
DOP2009000291A (es) 2010-01-31
US20130005703A1 (en) 2013-01-03
HK1143588A1 (zh) 2011-01-07
TWI478919B (zh) 2015-04-01
EP2185555B1 (en) 2016-03-16
US8293913B2 (en) 2012-10-23
CN101687866B (zh) 2014-06-04
JP5501230B2 (ja) 2014-05-21
IL202706A0 (en) 2010-06-30
RU2483068C2 (ru) 2013-05-27
UA99626C2 (ru) 2012-09-10
CN101687866A (zh) 2010-03-31
CA2691529A1 (en) 2009-02-12
JP2010535739A (ja) 2010-11-25
CO6251268A2 (es) 2011-02-21
CA2691529C (en) 2016-01-05
MX2009013956A (es) 2010-04-30
ES2574154T3 (es) 2016-06-15
ZA200909075B (en) 2013-03-27
EP2185555A1 (en) 2010-05-19
AU2008285652B2 (en) 2013-09-05
US20100292271A1 (en) 2010-11-18
IL202706A (en) 2014-08-31
TW200914453A (en) 2009-04-01
AU2008285652A1 (en) 2009-02-12
BRPI0812853A2 (pt) 2014-12-23
RU2010108282A (ru) 2011-09-20
NZ581986A (en) 2012-02-24
WO2009019286A1 (en) 2009-02-12
KR20100039300A (ko) 2010-04-15
CR11187A (es) 2010-05-27
US8440694B2 (en) 2013-05-14
ECSP099831A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
GT200900333A (es) Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
ECSP088826A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
UY31326A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
UY30729A1 (es) Derivados de pirrol, su preparacion y su utilizacion en terapéutica
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3